The Croatia Pharmaceuticals and Healthcare Report

    • Independent 5-year pharmaceutical and healthcare industry forecasts for Croatia.
    • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Croatian pharmaceutical and healthcare industry.
    • Competitive intelligence, Croatian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Croatian market.

The Croatia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2012 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Croatia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Croatian pharmaceutical and healthcare industry.

" "We find the Croatia Pharmaceuticals & Healthcare Report to be an effective review of the pharmaceutical industry and healthcare sector in Croatia. The Report contains full data and is very useful." "
Tatjana Sidnik-Milosevic, M.D. Director Institute of Immunology, Inc., Croatia

Key Benefits of Report

    • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Croatia to test other views – a key input for successful budgeting and strategic business planning in the Croatian pharmaceutical and healthcare market.
    • Target Business Opportunities & Risks in the Croatian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Croatia.
    • Exploit The Latest Competitive Croatian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Croatia.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

BMI's Executive Summary

[TOP]

The Croatian market is small and behind many of its regional neighbours, despite its relatively advanced status. At more than 70% by value, generics – comprising mostly relatively expensive branded generics – meet the bulk of demand for pharmaceuticals, with the segment continuing to be boosted by healthcare debts, cost-containment initiatives and the support for the strong domestic generics industry in the face of distinct intellectual property (IP) deficiencies.

As in many of its regional peers, prescription medicines in Croatia account for an estimated 85% of the market, largely reflecting the underdeveloped primary care network and the status of medical professionals in the country. The aim of joining the European Union (EU) in as early as 2009 or 2010 will stimulate healthcare system reform in Croatia, gradually leading to the development of a more comprehensive primary care network. Cost-containment pressures will similarly stimulate the growth of an over-the-counter (OTC) market, although the cost-consciousness of consumers will act as a brake on the sector's value development.

In BMI's new Q108 Business Environment Rankings for the major 15 Central and Eastern Europe (CEE) markets, Croatia is found in joint twelfth place, alongside Lithuania, and above only Ukraine and Serbia. The current situation, therefore, is not judged particularly favourable for conducting business in the country, with other markets viewed as offering more commercial potential to multinationals. However, Croatia's removal from the Office of the US Trade Representative (USTR)'s 2007 'Special 301' report, focusing on countries in violation of intellectual property rights (IPRs), indicates a definite improvement in the country's operating conditions.

In the meantime, the local industry remains strong. Pliva, recently acquired by US Barr, is the dominant local player, commanding around a quarter of total generics sales in the country. The acquisition will improve Pliva's access to foreign markets and the US in particular. In the meantime, foreign direct investment (FDI) is discouraged by the country's severe healthcare debt and delays in payments, although the government has relaxed its notoriously difficult reimbursement list inclusion policy somewhat in recent months, including more foreign-made drugs.

Contents

[TOP]

Chapter 1 - Executive Summary

Croatia Pharmaceuticals Industry SWOT

Croatia Political SWOT

Croatia Economic SWOT

Croatia Business Environment SWOT

Chapter 2 - Business Environment Rankings

Table: Central & Eastern Europe Pharmaceuticals Business Environment Ranking

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Market Summary

Chapter 4 - Regulatory Regime

Table: Croatian Product Approvals in 2006

Intellectual Property Regime

IP Deficiencies

Pricing & Reimbursement Regime

Healthcare System Deficit

Recent Pricing & Reimbursement Developments

Other Industry Developments

Chapter 5 - Industry Trends And Developments

Health Status

Table: Top 10 Causes of Death

Healthcare Expenditure

Healthcare Reforms

Domestic Pharmaceutical Industry

Foreign Company Activity

R&D Sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Drug market indicators

Key Growth Factors - Industry

Table: Health expenditure indicators

Key Growth Factors - Macroeconomic

Table: GDP, Output and Population

Prescription Market Forecast

Table: Hospital Sourced Drug Market Indicators

Table: Hospital Sourced Drug Market Indicators

OTC Market Forecast

Table: OTC Market Indicators

Generics And Branded Market Forecast

Table: Generics And Branded Market Indicators

Export/Import Forecasts

Table: Sectoral Trade Indicators

Key Risks To BMI's Forecast Scenario

Chapter 7 - Country Snapshot: Croatia Demographic Data

Section 1: Population

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Chapter 8 - Competitive Landscape

Table: Market Shares of Leading Companies (2004)

Chapter 9 - Foreign Company Profiles

GlaxoSmithKline

Pfizer

Sanofi-Aventis

Novartis

Merck & Co

Krka

Chapter 10 - Indigenous Company Profiles

Pliva

Belupo

Chapter 11 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 12 - Appendix: Regional Demographic Data

Wages (Ave Labour Force Per Annum), US$ PPP

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of European Pharmaceutical & Healthcare Sources

[TOP]

BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:

 

Read about our other Pharmaceuticals & Healthcare Reports

Asia Europe Middle East & Africa The Americas
UK
UAE
USA
[top]

 

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 24 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.